Objectives: To assess the effectiveness of high dose intravenous immunoglobulin (HDIVIG) in reducing the need for exchange transfusion in neonates with proven haemolytic disease due to Rh and/or ABO incompatibility. To assess the effectiveness of HDIVIG in reducing the duration of phototherapy and hospital stay.
Design: Systematic review of randomised and quasi-randomised controlled trials comparing HDIVIG and phototherapy with phototherapy alone in neonates with Rh and/or ABO incompatibility.
Results: Significantly fewer infants required exchange transfusion in the HDIVIG group (relative risk (RR) 0.28 (95% confidence interval (CI) 0.17 to 0.47); number needed to treat 2.7 (95% CI 2.0 to 3.8)). Also hospital stay and duration of phototherapy were significantly reduced.
Conclusion: HDIVIG is an effective treatment.
- intravenous immunoglobulin
- rhesus haemolytic disease
- ABO incompatibility
- exchange transfusion
- IVIG, intravenous immunoglobulin
- HDIVIG, high dose IVIG
- HDN, haemolytic disease of the newborn
- RR, relative risk
- RD, risk difference
- WMD, weighted mean difference
- CI, confidence interval
- NNT, number needed to treat
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.